RESPIRATORY SYNCYTIAL VIRUS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA RSV vaccine shows promise for older adults in major trial
⭐️ VACCINE ⭐️ CompletedThis study tested an experimental mRNA vaccine (mRNA-1345) to protect against RSV, a virus that can cause serious lung infections in older adults. About 3,300 people aged 50 and older received the RSV vaccine alone, or at the same time as a flu or COVID-19 booster. Researchers ch…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 19:49 UTC
-
New RSV vaccine shows promise for older adults in korea
⭐️ VACCINE ⭐️ CompletedThis study tested an RSV vaccine in 378 older adults (age 60+) in Korea to see if it is safe and helps the body fight the virus. Participants received either the vaccine or a placebo and were monitored for side effects and immune response. The results will help determine if the v…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 19:37 UTC
-
RSV booster study shows promise for older adults
⭐️ VACCINE ⭐️ CompletedThis study tested a booster dose of the experimental mRNA-1345 RSV vaccine in 507 adults aged 60 and older who had already received a licensed RSV vaccine at least 12 months earlier. The goal was to see if the booster was safe and boosted the body's immune defenses against RSV. R…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 14, 2026 12:04 UTC
-
Moderna tests multiple mRNA vaccines in one study
⭐️ VACCINE ⭐️ CompletedThis study tested several mRNA vaccines (for COVID-19, flu, RSV, and CMV) in 308 healthy adults aged 18 to 75. The main goal was to check safety and how well the vaccines triggered an immune response. Participants received one or more vaccines and were monitored for side effects …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 07, 2026 18:41 UTC
-
New RSV shot for babies shows strong protection in massive study
Disease control CompletedThis study looked at how well the medicine BEYFORTUS (nirsevimab) prevents serious RSV infections in babies. Nearly 50,000 infants were included, and researchers tracked doctor visits, hospital stays, and lab-confirmed RSV cases. The goal was to see if the shot reduces severe bre…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Disease control
Last updated May 13, 2026 16:00 UTC